Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Clascoterone is currently expensive and not yet available for hair loss treatment. The conversation discusses its potential future affordability.

The conversation discusses using minoxidil and Koshine for hair loss. It suggests applying them separately with a 5-minute gap and using Koshine on dry hair.

Ketoconazole shampoo is primarily used to reduce scalp fungus and inflammation, not to block DHT or androgen receptors. It may help with seborrheic dermatitis and improve scalp health, but its effects on hair loss are minimal compared to treatments like finasteride.

Using finasteride and peptides, including GHK-Cu, improved hair thickness and regrowth. The user also used a KLOW blend and CJC/IPA for better sleep and recovery.

Oral ketoconazole is discussed as a potential hair loss treatment, but it poses significant health risks like liver damage and adrenal insufficiency. Users suggest safer alternatives like topical anti-androgens or spironolactone, emphasizing the importance of consulting a specialist.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

Ketoconazole shampoo can dry out hair, causing it to become frizzy and less manageable. Users suggest using conditioner, trying different shampoos, or reducing the frequency of ketoconazole use to mitigate these effects.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

Minoxidil's effectiveness is limited by the need for sulfation and proper transport to hair follicles, with tretinoin potentially enhancing its effects by promoting enzyme activity and keratinocyte differentiation. Tretinoin may improve minoxidil's response by boosting the expression of necessary enzymes and transporters.

User phoenixblue asked about hair fiber products like Toppik and if they cause hair loss by clogging pores. Replies suggested that Toppik is safe, but effectiveness varies; some users experienced no hair loss, while others had issues with color or sweating.

PP405 is progressing rapidly through trials, with mixed opinions on its potential effectiveness. Current treatments like minoxidil and finasteride are still widely discussed, with some users reporting positive results from new formulations.

Norwood 7 hair loss is often excluded from trials to ensure treatments appear more effective and to reduce costs. Some believe treatments effective for Norwood 5 could work on Norwood 7, but companies prioritize market readiness.

Different minoxidil formulations affect hair growth and side effects. Higher propylene glycol and pH levels improve effectiveness but can cause scalp irritation.

Hair loss discussion mentions Minoxidil, finasteride, and RU58841 treatments. Regenepure shampoo's ketoconazole ingredient causes confusion due to inconsistent listings.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.

Ketoconazole can slightly improve hair density and is best used as an adjunct to treatments like finasteride and minoxidil. It helps with scalp health but won't stop androgenetic alopecia on its own.

The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.

The user experienced severe scalp issues and hair loss after using ketoconazole shampoo, which worsened despite various treatments. They seek advice on restoring scalp health, suspecting an allergic reaction or imbalance caused by the shampoo.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

Kintor is launching pyrilutamide as a cosmetic for hair loss. Users discuss its potential, comparing it to Cosmerna.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.